Your browser doesn't support javascript.
loading
Cost-effectiveness of repeat delayed imaging for spontaneous subarachnoid hemorrhage.
Shang, Wenru; Jin, Huajie; Vastani, Amisha; Mirza, Asfand Baig; Fisher, Benjamin; Kalra, Neeraj; Anderson, Ian; Kailaya-Vasan, Ahilan.
  • Shang W; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Jin H; WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou University, Lanzhou, China.
  • Vastani A; King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom.
  • Mirza AB; King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom.
  • Fisher B; Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, United Kingdom.
  • Kalra N; Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, United Kingdom.
  • Anderson I; Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, United Kingdom.
  • Kailaya-Vasan A; Department of Neurosurgery, Leeds Centre for Neurosciences, Leeds General Infirmary, Leeds, United Kingdom.
PLoS One ; 18(7): e0289144, 2023.
Article en En | MEDLINE | ID: mdl-37494367
ABSTRACT

BACKGROUND:

In patients with intracranial aneurysm presenting with spontaneous subarachnoid hemorrhage (SAH), 15% of them could be missed by the initial diagnostic imaging. Repeat delayed imaging can help to identify previously undetected aneurysms, however, the cost-effectiveness of this strategy remains uncertain.

OBJECTIVE:

The aim of this study is to assess the cost-effectiveness of repeat delayed imaging in patients with SAH who had a negative result during their initial imaging.

METHODS:

A Markov model was developed to estimate the lifetime costs and quality-adjusted life-year (QALY) for patients who received or not received repeat delayed imaging. The analyses were conducted from a healthcare perspective, with costs reported in UK pounds and expressed in 2020 values. Extensive sensitivity analyses were performed to assess the robustness of the results.

RESULTS:

The base case incremental cost-effectiveness ratio (ICER) of repeat delayed imaging is £9,314 per QALY compared to no-repeat delayed imaging. This ICER is below the National Institute for Health and Care Excellence (NICE) £20,000 per QALY willingness-to-pay threshold. At the NICE willingness-to-pay threshold of £20,000 per QALY, the probability that repeat delayed imaging is most cost-effective is 0.81. The results are sensitive to age, the utility of survived patients with a favorable outcome, the sensitivity of repeat delayed imaging, and the prevalence of aneurysm.

CONCLUSIONS:

This study showed that, in the UK, it is cost-effective to provide repeat delayed imaging using computed tomographic angiography (CTA) for patients with SAH who had a negative result in their initial imaging.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article